Wistar Institute researchers found that the neurotransmitter neuromedin U suppresses T cell infiltration at the earliest stage of neuroendocrine prostate cancer, and blocking it restored sensitivity to immunotherapy in experimental models.
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.